Clinical trials: High-Risk Cancer, open to volunteers
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived…
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia
- Trial name
- NCT05292664
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew E. Place, MD
Osteosarcoma, Pediatric Osteosarcoma
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor.
- Conditions
- Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- FOSTER (NCT07871864)
- Testing
- Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
- Where
- 77 sites in Denmark, Finland and 6 more
- Volunteers
- 530 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Intrahepatic Cholangiocarcinoma
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
- Trial name
- NCT06664021
- Testing
- Tislelizumab combined with S-1
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Cervical Cancer, Cervical Cancer Screening
Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine
In 2020, a cervical screening center was established in Zaporizhzhia (Ukraine), initiating a pilot project to evaluate the prevalence of HPV among women in Eastern Ukraine.
- Conditions
- Cervical Cancer, Cervical Cancer Screening, Human Papillomavirus (HPV) Infection, Cervical Intraepithelial Neoplasia
- Trial name
- NCT07275333
- Testing
- HPV Self-Sampling Kit
- Where
- Ukraine
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Prostate Cancer
¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer
Multiparametric magnetic resonance imaging (mpMRI) is the standard imaging modality for prostate cancer diagnosis and focal therapy planning.
- Trial name
- FOCUS-PSMA (NCT07788625)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
ctDNA, Chemotherapy
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX/CAPOX for 6 months) or the intervention group (FOLFOX/CAPOX plus bevacizumab for 6 months) to receive adjuvant therapy.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-04 (NCT07562490)
- Testing
- FOLFOX, Folfox plus Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study
This is a randomized, non-comparative, open-label, two-arm phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab plus induction chemotherapy versus adebrelimab plus SHR-8086…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors, Immunotherapy
- Trial name
- CATALIS (NCT07266025)
- Testing
- Adebrelimab, XELOX, SHR-8068
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Colorectal Cancer, Microsatellite Instability High
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
The PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer.
- Conditions
- Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
- Trial name
- PICC-3 (NCT06903858)
- Testing
- Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Recurrent High Grade Glioma
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhanced delivery (CED) in…
- Trial name
- PuMP (NCT06126744)
- Testing
- MVR-C5252
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Prostate Cancer, Localized Prostate Carcinoma
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits…
- Trial name
- NCT02526368
- Testing
- Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Ivan de Kouchkovsky, MD
Glioblastoma Multiforme of Brain, Glioma
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic…
- Conditions
- Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
- Trial name
- NCT07464925
- Testing
- GLIX1
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tetragon Biosciences Ltd
Breast Cancer Female
High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study
Monocentric prospective study evaluating the efficacy of High intensity focused ultrasound (HIFU) in breast tumors.
- Trial name
- BRIFU (NCT03342625)
- Testing
- High Instensity Focused Ultrasound
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Institut Bergonié
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined…
- Conditions
- Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03418038
- Testing
- Ascorbic Acid, Carboplatin, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death.
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
- Trial name
- NCT07223385
- Testing
- Cardio-Oncology Referral, Notification to PCP/General Cardiologist
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Lymphoma, B-Cell
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL).
- Trial name
- axi-cel (NCT06609304)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhengzhou University
Glioblastoma
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
Brief Summary The goal of this clinical trial is to learn whether intensified adjuvant treatment is safe and may help delay disease progression in adults with high-risk newly diagnosed glioblastoma.
- Trial name
- NCT07670026
- Testing
- Sintilimab, Bevacizumab, Postoperative Radiotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.